Vabomere (Meropenem-Vaborbactam)

Vabomere (meropenem and vaborbactam) is a combination of meropenem, a penem antibacterial, and vaborbactam, a beta-lactamase inhibitor, used for the treatment of patients aged 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex. 

Note: Prescribing Vabomere medicine in the absence of a proven or strongly suspected bacterial infection is unlikely to offer benefit to the patient and may increase the probability of drug-resistant bacteria. 

Recommended Dosage: Medicine Vabomere is supplied as a dry powder in a single-dose vial that must be constituted and further diluted before intravenous infusion as outlined below. This medication does not contain preservatives. Aseptic technique must be considered for constitution and dilution.

The recommended dosage is 4 grams (meropenem 2 grams and vaborbactam 2 grams) administered every 8 hours by intravenous (IV) infusion over three hours in patients aged 18 years and older with an estimated glomerular filtration rate (eGFR) greater than or equal to 50 mL/min/1.73m². The time-span of treatment is for up to two weeks (14 days).

Dosage adjustment is recommended in those with renal impairment who have an eGFR less than 50 mL/min/1.73m². The recommended dosage in patients with varying degrees of renal function is as follows:

• Vabomere 2 grams (meropenem 1 gram and vaborbactam 1 gram) administered every 8 hours by intravenous (IV) infusion with an estimated glomerular filtration rate (eGFRa) 30 mL/min/1.73m² to 49 mL/min/1.73m².
• Vabomere 2 grams (meropenem 1 gram and vaborbactam 1 gram) administered every 12 hours by intravenous (IV) infusion with an estimated glomerular filtration rate (eGFRa) 15 mL/min/1.73m² to 29 mL/min/1.73m².
• Vabomere 1 gram (meropenem 0.5 grams and vaborbactam 0.5 grams) administered every 12 hours by intravenous (IV) infusion with an estimated glomerular filtration rate (eGFRa) less than 15 mL/min/1.73m².

For those with changing renal function, monitor serum creatinine concentrations and eGFR at least daily and adjust the dosage accordingly. 

Meropenem and vaborbactam are removed by hemodialysis. For those maintained on hemodialysis, administer Vabomere after a hemodialysis session.

• Use of Vabomere 2 gram is restricted in those with known hypersensitivity to any existing components of Vabomere (meropenem-vaborbactam), or to other medicines in the same group or in those who have showed anaphylactic reactions to beta-lactam antibacterial medicines. 
• Hypersensitivity reactions may occur in patients treated with medicine Vabomere. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and some serious skin reactions may also occur in patients receiving treatment with beta-lactam antibacterial medicines. If an allergic reaction to drug Vabomere occurs, discontinue the treatment immediately.
• Seizures and some other adverse Central Nervous System (CNS) experiences may occur during therapy with meropenem, which is a component of Vabomere 2 gram. These experiences may occur most commonly in those with CNS disorders or with bacterial meningitis or compromised renal function. Close adherence to the standard dosage regimens is urged, mainly in those with known factors that predispose to convulsive activity. 
• Clostridium difficile-associated diarrhea (CDAD) may occur with use of nearly all antibacterial agents, including Vabomere 2 gram, and may range in severity from mild diarrhea to fatal colitis. Therapy with antibacterial agents alters the normal flora of the colon that leads to excess growth of C. difficile. In case CDAD is suspected/confirmed, discontinue the use of ongoing antibacterial medicine. Apt fluid and electrolyte management, protein supplementation, antibacterial drug therapy of C. difficile, and surgical assessment must be done as clinically required.
• Avoid concomitant use of Vabomere and divalproex sodium or valproic acid. Consider the use of antibacterial medicines other than carbapenems for treating infections in those whose seizures are well controlled on divalproex sodium or valproic acid. If use of Vabomere is essential, consider supplemental anticonvulsant therapy. 
• In patients receiving treatment with vabomere injection and with renal impairment, thrombocytopenia has been noted in those treated with meropenem, but no clinical bleeding has been noted. 
• Alert patients taking Vabomere on an outpatient basis regarding side effects such as delirium, seizures, headaches or paresthesias that could interfere with mental alertness or cause motor impairment. Until it is reasonably well established that this medicine is well tolerated, patients should not operate any machinery or motorized vehicles. 
• As with other existing antibacterial medicines, prolonged use of Meropenem and Vaborbactam may result in overgrowth of nonsusceptible organisms. Repeated assessment of the patient is required. If superinfection does occur during treatment, apt measures need to be taken.

What documents are required to import VABOMERE to India?

VABOMERE (Meropenem-Vaborbactam) injection can be imported by patients or government hospitals on the name of the patients only. 

The following documentation required to import the product:

Valid prescription from a qualified doctor.

• Patients diagnostic reports
• Patients Identity Proof (issued by government of India)

How does order be confirmed?

The order will be confirmed only after the receipt of:

• Valid prescription of Doctor
• Import permit if applicable

Is VABOMERE available in India?

VABOMERE (meropenem-vaborbactam injection) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input

• On availability of Vabomere in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
• Medicine Price.
• Finding Genuine and reliable source from Canada, Europe, USA and Australia
• Ensuring 100% transparency.

VABOMERE can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.

IPN (Indian Pharma Network) can facilitate the supply of VABOMERE (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable). 

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Vabomere price in India. 

We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network is able to source VABOMERE (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma Network offers its customers worldwide access to the best available treatment.

Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Vabomere®?

Meropenem-Vaborbactam is Generic Name for the trade name drug Vabomere®.

What is the Manufacturer Name of Vabomere®?

Vabomere® is manufactured by The Medicines Company. 

Is Vabomere® approved by the FDA?

Yes, Vabomere® is approved by the FDA. Date of first/initial approval: August 29, 2017.

Where can I get Vabomere® at the best price in India?

To get the best Vabomere injection price in India, kindly contact Indian Pharma Network (a WHO GDP & ISO 9001:2008 authorized Company). For Vabomere®, a valid medical prescription is required from your treating doctor.

What is the dosage and form of Vabomere®?

Vabomere® 2 grams (meropenem and vaborbactam) for injection, is supplied as powder for constitution in single-dose, clear glass vials containing meropenem 1 gram (equivalent to 1.14 grams meropenem trihydrate) and vaborbactam 1 gram. 

What are the most common side effects with Vabomere? 

The most common side effects with Vabomere® include: phlebitis/infusion site reactions, headache, and diarrhea. 

How much does Vabomere® cost in India?

The cost of Vabomere (meropenem and vaborbactam) in India is less and can vary. In order to buy this cUTI drug authentically, you can Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Vabomere?

Store the vials of Vabomere at 20°C to 25°C (68°F to 77°F); excursions are permitted to 15°C to 30°C (59°F to 86°F).

Is it safe to buy Vabomere online from India? 

Yes, You can buy Vabomere online at the best price from the Indian Pharma Network (IPN) if Vabomere has not been approved or is not available in your country.

What are the Highlights of prescribing information for Vabomere?

Click Here to download full Vabomere prescribing information.